Lupuzor™ is a potential treatment for lupus. It has been given the 'Gold Standard' approval by the US FDA for its Phase III programme with a Sprecial Protocol Assessment (SPA) and fast track designation. Lupuzor™ has now commenced its pivotal Phase III trial. ImmuPharma holds all worldwide rights in this lead compound.